MedTrace Logo

Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer

NCT00093522 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2013-12-19

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with fludarabine may kill more tumor cells.

PURPOSE: This randomized phase II trial is studying vaccine therapy and fludarabine to see how well they work compared to vaccine therapy alone in treating patients with stage IV kidney cancer.

Conditions

Interventions

BIOLOGICAL

autologous tumor cell vaccine

BIOLOGICAL

keyhole limpet hemocyanin

BIOLOGICAL

therapeutic autologous dendritic cells

DRUG

fludarabine phosphate

PROCEDURE

conventional surgery

Sponsors & Collaborators

  • St. Luke's Medical Center

    lead OTHER

Principal Investigators

  • John P. Hanson, MD · St. Luke's Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00093522 on ClinicalTrials.gov